{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:46Z","timestamp":1792511926813,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01768-3","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:02:45Z","timestamp":1783400565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The strategic importance of mRNA vaccine technologies in Africa for achieving public health independence"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-8995","authenticated-orcid":false,"given":"Patrick B.","family":"Arbuthnot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5796-7720","authenticated-orcid":false,"given":"Kristie M.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9033-7536","authenticated-orcid":false,"given":"Dylan M.","family":"Kairuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2359-4011","authenticated-orcid":false,"given":"Connor","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-917X","authenticated-orcid":false,"given":"Robin","family":"Klintworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-5130","authenticated-orcid":false,"given":"Charles B.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-2436","authenticated-orcid":false,"given":"Abdullah","family":"Ely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"1768_CR1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2356143","volume":"13","author":"H Liao","year":"2024","unstructured":"Liao, H., Lyon, C. J., Ying, B. & Hu, T. Climate change, its impact on emerging infectious diseases and new technologies to combat the challenge. Emerg. Microbes Infect. 13, 2356143 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"1768_CR2","unstructured":"Africa Centres for Disease Control & Prevention. Moving forward the vaccine supply chain in Africa, https:\/\/africacdc.org\/news-item\/moving-forward-the-vaccine-supply-chain-in-africa\/ (2025)."},{"key":"1768_CR3","unstructured":"World Health Organization. COVID-19 Situation, https:\/\/www.who.int\/europe\/emergencies\/situations\/covid-19 (2025)."},{"key":"1768_CR4","unstructured":"Organisation for Economic Co-operation & Development. Access to COVID-19 Vaccines: Global Approaches in a Global Crisis. https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2021\/03\/access-to-covid-19-vaccines-global-approaches-in-a-global-crisis_c34ca5e0\/c6a18370-en.pdf (2021)."},{"key":"1768_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1768_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","volume":"592","author":"H Tegally","year":"2021","unstructured":"Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438\u2013443 (2021).","journal-title":"Nature"},{"key":"1768_CR7","unstructured":"Maxmen, A. Unseating big pharma: the radical plan for vaccine equity. Nature 607, 226\u2013233 (2022). The article highlights the need for sustainable vaccine manufacturing capacity in low- and middle-income countries, including Africa, to reduce dependence on external suppliers and improve preparedness for future pandemics."},{"key":"1768_CR8","unstructured":"Medicines Patent Pool. What We Do: mRNA Technology Transfer Programme, https:\/\/medicinespatentpool.org\/what-we-do\/mrna-technology-transfer-programme (2025)."},{"key":"1768_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/d44148-025-00179-1","author":"E Duvenage","year":"2025","unstructured":"Duvenage, E. Cheaper mRNA vaccines in a nutshell. Nat. Afr. https:\/\/doi.org\/10.1038\/d44148-025-00179-1 (2025).","journal-title":"Nat. Afr."},{"key":"1768_CR10","unstructured":"de Koning, C. et al. Methods of valorising cashew nut shell liquid (CNSL) and\/or a component thereof. WO2025062315 https:\/\/patentscope.wipo.int\/search\/en\/WO2025062315 (2025)."},{"key":"1768_CR11","unstructured":"Afrigen Biologics & Vaccines. Afrigen celebrates GMP certification by SAHPRA \u2013 a landmark achievement demonstrating that Africa can build and sustain world-class regulated health manufacturing capacity https:\/\/za.linkedin.com\/company\/afrigen-biologics-pty-ltd (2026)."},{"key":"1768_CR12","unstructured":"Afrigen Biologics & Vaccines. Elevating mRNA manufacturing toward GMP-readiness for vaccine candidate AfriVac 2121 (Wuhan) under the WHO\/MPP mRNA Technology Transfer Programme https:\/\/www.afrigen.co.za\/2025\/08\/29\/elevating-mrna-manufacturing-toward-gmp-readiness-for-vaccine-candidate-afrivac-2121-wuhan-under-the-who-mpp-mrna-technology-transfer-programme\/ (2025)."},{"key":"1768_CR13","unstructured":"World Health Organization. mRNA Technology Transfer Programme. https:\/\/www.who.int\/initiatives\/mrna-technology-transfer-%28mrna-tt%29-programme. (World Health Organization, 2026)."},{"key":"1768_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/vaccines13060646","volume":"13","author":"A Duga","year":"2025","unstructured":"Duga, A. et al. Strengthening National Regulatory Authorities in Africa: A Critical Step Towards Enhancing Local Manufacturing of Vaccines and Health Products. Vaccines (Basel) 13, 646 (2025). The article highlights that development of sustainable vaccine manufacturing capacity in Africa depends not only on production infrastructure and technical expertise, but also on strong regulatory oversight provided byt National Regulatory Authorities.","journal-title":"Vaccines (Basel)"},{"key":"1768_CR15","unstructured":"Gates Foundation. Gates Foundation to Accelerate mRNA Vaccine Innovation and Manufacturing in Africa and Globally https:\/\/www.gatesfoundation.org\/ideas\/media-center\/press-releases\/2023\/10\/mrna-vaccine-manufacturing-africa (2023)."},{"key":"1768_CR16","unstructured":"QuantoomBiosciences. Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences https:\/\/quantoom.com\/africa-and-europe-join-forces-to-revolutionize-rna-based-vaccines-and-therapeutics-production-mou-signed-between-eva-pharma-dna-script-quantoom-biosciences (2025)."},{"key":"1768_CR17","unstructured":"BioNTech. Update on First BioNTainer for African-based mRNA Manufacturing. https:\/\/investors.biontech.de\/news-releases\/news-release-details\/update-first-biontainer-african-based-mrna-manufacturing (2022)."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01768-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:03:10Z","timestamp":1783400590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01768-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1768"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01768-3","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are founders of Green Lipids (Pty) Ltd, Johannesburg, South Africa.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"380"}}